Fourth dose of BNT162b2 vaccine for patients with autoimmune rheumatic diseases in a nationwide setting
Main finding · COVID-19 infectionResult — go to the resultHazard ratio 0.54 95% CI 0.52–0.58Authors' conclusion
A fourth BNT162b2 vaccination of ARD patients was associated with favourable outcomes compared with three doses among patients with no history of COVID-19 infection.
Study context
- Population
- ARD patients aged 18 years or older without previous COVID-19 infection, Clalit Health Services, Israel, 16 January 2022 to 31 March 2022 (Omicron predominant)
- Participants
- 43,748 patients
- Exposure
- Fourth dose of BNT162b2 vs three doses
- Fourth dosen = 15,982
- Controln = 27,766reference
- Outcome
- COVID-19 infection
Methodological detailsnationwide, multivariate Cox regression
- Nationwide
- Multivariate Cox regression
Main finding
As reported in the abstract
Hazard ratio
0.54
95% CI 0.52–0.58
P < 0.001
Events by group
Fourth dosevs Control
HR 0.54 (95% CI 0.52–0.58); P < 0.001
Observational data: associations, not effects.
Secondary outcomes
COVID-19-related hospitalization (secondary)
- Fourth dose vs control: similar association (lower risk) for COVID-19-related hospitalization
- HR 0.36, 95% CI 0.22, 0.61
COVID-19-related death (secondary)
- Fourth dose vs control: similar association (lower risk) for COVID-19-related death
- HR 0.41, 95% CI 0.24, 0.71
Original publication
Fourth dose of BNT162b2 vaccine for patients with autoimmune rheumatic diseases in a nationwide setting. Rheumatology (Oxford). Published 10 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →